Ближайший уровень поддержки по SPY – 200.30 уровень сопротивления – 200.60
AMGN смотрим на покупку выше 137
CMCM смотрим за ним
Gapping up/down: EXPR +14% and ARUN +8% after earnings, MNKD +4% after initiation with Buy at Jefferies; SWHC -11% and TIVO -2% after earnings, LEJU -4% after dg at GS
Gapping up
In reaction to strong earnings/guidance: TUBE +32.5%, EXPR +13.9%, ARUN +8%, DCI +5.7%, NMBL +2.9%, TIF +2.7%, HEI +2.3%, REX +1.8%, BWS +1.4%
M&A news: OIBR +1.8% (Engagement of Banco BTG Pactual to act as agent to review alternatives to the acquisition of the shares of TIM)
Other news: ISNS +25.9% (seeing continued strength — another recent security play, ie DGLY, TASR), AEGR +8.2% (announces resolution of warning letter for JUXTAPID (lomitapide) capsules), PKT +6.9% (receives $5 mln in initial orders from Tier 1 European MSO), ALTV +5.4% (following late move higher on Juniper Investment Company amended 13D filing with proposal for an all-cash acquisition of $8/share), RSH +4.7% (continued strength following yesterday's rumors on potential financing), RYAAY +3.6% (launched Ryanair Business Plus), PT +3.5% (still checking), CLUB +3.4% (Farallon Capital files amended 13D; indicates company should be prepared to evaluate potential acquirers' interest and engage financial advisor ), YOKU +3.3% (announces up to $300 mln share repurchase program), HZNP +2.5% (announces the USPTO issuance of an additional notice of allowance with claims covering RAYOS delayed-release tablets), ARO +2.1% (in sympathy with EXPR), MBLY +1.9% (cont strength), GALE +1.7% (still checking), KLIC +1.7% (authorized the repurchase of up to $100 mln of co's common shares), TRNS +1.4% (co increased secured revolving credit facility to $30 mln, up from $20 mln; $15 mln now available for acquisitions, up from previous $10 mln), ALLT +1.2% (in sympathy with PKT (closest peer)), DGLY +1.2% (cont momentum), BRCM +1.2% (Netatmo has selected the Broadcom Wireless Internet Connectivity for Embedded Devices Wi-Fi technology), LGND +1% (partner GSK receives FDA approval for Promacta/Revolade for use in patients with severe aplastic anemia), GSK +1% (receives FDA approval for Promacta/Revolade for use in patients with severe aplastic anemia), STJ +0.9% (resolves FDA Warning Letter for Plano Facility)
(
Читать дальше )